Managing Bone Metastases in Prostate Cancer

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will benefit from intensified treatment.

CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.

Patients with nonmetastatic prostate cancer treated according to NCCN Guidelines are more likely to die of other natural causes than from their cancer.

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic castration-sensitive prostate cancer.